On June 28, Daiichi Sankyo's innovative drug Delijing®(Mirogabalin Besylate Tablets, Trade Name: Tarlige)®) has been approved by the National Medical Products Administration (NMPA) for the treatment of diabetic peripheral neuropathic pain (DPNP) in adults.
China, as the world's largest diabetes country, has a staggering 140 million people with diabetes.1Moreover, diabetes can lead to various complications, among which diabetic neuropathy (DN) is the most common chronic complication. The resulting diabetic peripheral neuropathic pain (DPNP) severely affects the quality of life of diabetic patients, potentially causing disability and mental health issues. However,Due to the relatively limited drug treatment options for DPNP, patients often fail to receive timely and effective treatment, and there is an urgent need for better therapeutic approaches.This time, Daiichi-Sankyo®The successful approval is not only an important milestone in the field of DPNP treatment, but also provides a better new treatment option for the treatment difficulties in this field over the years, enriching the choice of clinical drugs and bringing a new dawn of treatment to patients with DPNP in China.In this regard, Ms. Li Li, General Manager of the Basic Medical Care Business Headquarters of Daiichi Sankyo (China), was specially interviewed.
▲Ms. Li Li, General Manager of the Primary Healthcare Division Headquarters of Daiichi Sankyo (China)Deeply Engaged in the Field of Pain Management, Meeting Unmet Patient NeedsDaiichi Sankyo has been deeply engaged in the field of pain management since entering the Chinese market. Through continuous innovation in drug development, the company is committed to providing patients with safer and more effective high-quality medications to meet the urgent treatment needs of patients in China. Ms. Li Li pointed out,This time, Daiichi-Sankyo®The approval has added another重磅 product to Daiichi-Sankyo's pain management portfolio in China.Delijing®As a third-generation highly selective calcium channel modulator, it can rapidly improve pain in patients with DPNP and provide long-term benefits to patients.
Daiichi Sankyo®It was approved for marketing in Japan in 2019 and has since accumulated a large amount of evidence-based medical evidence and rich clinical practice experience with patients. Meanwhile, both the American Diabetes Association and the American Academy of Neurology guidelines recommend mirogabalin as a treatment option for DPNP.1.2Ms. Li Li said, "We believe that with the silence of Daiichi Sankyo®The approval and launch in China brings a new and effective treatment option for DPNP patients.Driven by Patient Needs, Accelerating the Implementation of Innovative SolutionsIn Daiichi Sankyo's global layout, China has always been one of the important strategic markets. Ms. Li Li introduced that the planning of Daiichi Sankyo (China) has always been closely following the needs of Chinese patients, continuously upgrading and optimizing.Through its existing basic healthcare division products and upcoming groundbreaking innovative drugs, jointly supporting its healthcare endeavors in China.Territory.
Daiichi Sankyo®As the first original imported innovative drug for the treatment of DPNP, its launch will provide a "new engine" for the development of Daiichi Sankyo (China) in the field of pain management in China.Ms. Li Li said, "Our team has already prepared for Delijing."®We are fully prepared for the commercial launch, striving to ensure more patients can timely benefit from our innovative treatment solutions, free from pain and take a further "quiet" step. In addition, we will implement strategic focus and execution plans through optimized resource allocation to maximize product lifecycle management. Adhering to the concept of "patient-centeredness," we are actively expanding Delijing.®The ecosystem collaboration actively promotes the accessibility of medicines with e-commerce and retail partners, benefiting more patients in China. In the future, we will also continue to accelerate innovation in research and development, constantly enrich our product pipeline, and bring more efficient treatment options to patients.（AD-105-2024-000509）
1. The IDF Diabetes Atlas. 10th. China Country report; 2021.2. Diabetes Care . 2024 Jan 1;47(Suppl 1):S158-S178.3. Raymond Price, et al. Neurology. 2022 Jan 4;98(1):31-43.
First Trial | Huang Jia
Second Review | Li Fangchen
Third Review | Li Jingzhi
